Although encouraging survival statistics are now reported after allogeneic hematopoietic stem cell transplantation (allo-HSCT), pulmonary complications represent major causes of morbidity and mortality. 1 Smoking is known to be associated with increased risk of various diseases, and can be a risk factor for respiratory tract infection in immunocompetent patients. 2 In patients with AML, smoking has been reported to increase the rate of pulmonary infections during induction chemotherapy. 3 In allo-HSCT, several studies have reported the impact of smoking on transplant outcomes. Some reports have reported smoking before allo-HSCT to be correlated with poor transplant outcomes such as lower overall survival (OS), 4, 5 disease-free survival (DFS) 4 and increased non-relapse mortality (NRM) or disease relapse. 4 Conversely, other studies have shown no apparent association between smoking and mortality after HSCT. 6, 7 An association between smoking and post-transplant pulmonary complications has also been reported in some studies. However, these reports were limited to only severe cases, and the clinical impact of smoking on the entire spectrum of pulmonary complications remains unclear. Therefore, we retrospectively analyzed 286 patients aged ⩾ 20 years with hematological disorders who underwent their first allo-HSCT at our hospital between 2005 and 2010. We evaluated the impact of tobacco smoking before allo-HSCT on clinical outcomes, with particular focus on pulmonary complications.
The tobacco consumption of each patient was evaluated by the Brinkman Index (BI). 8 The BI was calculated by multiplying the number of cigarettes smoked per day by the duration of smoking (years). The study patients were classified into three smoking groups according to BI: never smokers (BI = 0, n = 126); low-dose smokers (0 oBI o 400, n = 93) and high-dose smokers (BI ⩾ 400, n = 67). For patients with ⩾ 2 pulmonary events, only the first event was analyzed.
Patient characteristics are summarized in Table 1 . The patients in the high-dose smokers group were older, predominantly male and received reduced-intensity regimen and tacrolimus-based GvHD prophylaxis more frequently than the patients in the other groups (Table 1) . Neither forced expiratory volume in 1 s nor percent of predicted forced vital capacity values were significantly different among the three groups. The median follow-up period after HSCT was 1165 days (36-2375 days). Ninety patients eventually developed pulmonary complications at a median of 184.5 days (7-803 days) after HSCT. The cumulative incidence of pulmonary complications was 26% in the never smokers group, 36% in the low-dose smokers group and 46% in the high-dose smokers group (P = 0.02, Figure 1a ). Pulmonary complications seemed to develop in a dose-dependent manner. High-dose smoking (BI ⩾ 400) was significantly associated with a higher incidence of pulmonary complications in both univariate (relative risk (RR) 2.02, 95% confidence interval (CI) 1.21-3.35, P o0.01) and multivariate analysis (RR 1.78, 95% CI 1.06-3.00, P = 0.03) (Supplementary Table 1 ). The BI score was also associated with Abbreviations: BI = Brinkman index; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity. a Categorical variables were compared using the χ pulmonary complications in both univariate (RR 1.01, 95% CI 1.00-1.01, P o0.01) and multivariate analysis (RR 1.01, 95% CI 1.00-1.01, P = 0.02), even when BI was treated as a continuous variable (Supplementary Table 1) .
Pneumonia was the main cause of pulmonary complications, and occurred in 17% of patients in the never smokers group, 25% in the low-dose smokers group and 33% in the high-dose smokers group (P = 0.02, Supplementary Table 2 ). The rates of other causes of pulmonary complications, including non-infectious complications, were almost similar among the three groups, although the number of patients was limited.
In previous studies, smoking has been reported to be a significant risk factor for the development of pulmonary complications after allo-HSCT. Savani et al. 9 reported that pretransplant smoking history was associated with increased NRM from pulmonary causes, most of which were idiopathic pneumonia syndrome. Similarly, Tran et al. 7 reported that smoking dose was linked with an increased risk of respiratory failure within 100 days after transplantation. Conversely, Ho et al. 10 showed that smoking history was not associated with increased severe pulmonary complications, defined as diffuse alveolar hemorrhage, need for mechanical ventilation, or death from respiratory failure.
These differences in findings may be owing to the definition of pulmonary complications and the subject population of the studies. However, the results of the present study indicate that smoking can increase the risk, not only for life-threatening pulmonary events, but also for the entire range of posttransplant pulmonary complications, especially for pulmonary infections. Impaired mucociliary clearance, reduced phagocytosis and lower secretion of cytokines by alveolar macrophages observed in smokers may promote their susceptibility to pulmonary infections after allo-HSCT. 11 In addition, microbial virulence and antibiotic resistance promoted by smoking may also advance the development of post-transplant pulmonary infections.
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In the present study, OS adjusted for age, sex, type of conditioning regimen and GvHD prophylaxis was similar among the three groups (Figure 1b) . Disease relapse/progression was the most common cause of death, and pneumonia was the second or third leading cause of death in all three groups (Supplementary Table 3 ). NRM at 3 years after allo-HSCT was 20%, 22% and 24% (P = 0.84, Figure 1c) , and the cumulative incidence of relapse at 3 years was 29%, 25% and 35% in the never, low-dose and high-dose smokers groups, respectively (P = 0.36, Figure 1d ). DFS adjusted for age, sex, conditioning regimen and GvHD prophylaxis was similar among the three groups (Figure 1e) .
Several studies have examined the association between cigarette smoking and post-transplant survival or relapse. In a large retrospective study of CML patients by Marks et al., 4 high-dose smoking was associated with significantly reduced OS, DFS and increased NRM. Ehlers et al.
5 also reported that current smoking appeared to adversely affect OS. However, the results of the present study showed that pre-transplant high-dose smoking did not affect OS, DFS and NRM. In the study by Marks et al., all patients were conditioned by a myeloablative regimen and bone marrow transplantation was performed more frequently compared with the patients in the present study. In addition, smoking dose did not affect the post-transplant outcomes in unrelated HSCT. 4 Ehlers et al. 5 analyzed acute leukemia patients, including those undergoing both autologous and allogeneic transplantation; the majority of the patients were conditioned by cyclophosphamide and TBI. The present study included various hematological malignancies. Furthermore, 208 of 286 (72%) patients received HSCT from unrelated donors and 66 (23%) patients were conditioned by a reduced-intensity conditioning regimen. Cumulative incidence of pulmonary complications (a), adjusted probability of OS (b), NRM (c), the cumulative incidence of relapse (d), and adjusted probability of DFS (e) after allo-HSCT according to smoking dose. Adjusted probabilities of OS and DFS were compared using the Cox proportional hazards regression model. Cumulative incidences of pulmonary complications, NRM and relapse were estimated using the cumulative incidence function method and compared using Gray's test.
Thus, differences between patients and transplant backgrounds may affect the outcomes. With regard to disease relapse, study results have been somewhat conflicting. Smoking was associated with disease relapse in some studies 6, 7 but not in another study 4 or in the present study. These discrepancies may also be due to differences between patients and transplant backgrounds.
The present study had some limitations. First, given the retrospective nature of the study, some pulmonary complications may have been missed despite the detailed database and extensive chart review. In addition, we analyzed only the first episode if the patients had multiple pulmonary events. Thus, the incidence of late-onset pulmonary complications may have been underestimated. The second limitation is that the heterogeneous backgrounds of the patients may have biased our results, although we adjusted the factors in the multivariate analyses. The third limitation is that we could not follow the patients' smoking status after allo-HSCT, which might influence transplant outcomes.
In summary, the findings of the present study indicated that pretransplant tobacco smoking as measured by BI is an independent risk factor for the development of infectious pulmonary complications in a dose-dependent manner after allo-HSCT. Further prospective studies are warranted to confirm whether early smoking cessation would decrease the incidence of pulmonary complications after allo-HSCT.
